Evidence map›Paper›PMID 35128211›Full record

ReviewJACC. Basic to translational science2022

Translation of New and Emerging Therapies for Genetic Cardiomyopathies.

Adam S Helms, Andrea D Thompson, Sharlene M Day

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Basic to translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Gene therapy for cardiac arrhythmias.Nature reviews. Cardiology · 2026
    Review
  8. Genetic Dilated Cardiomyopathy: A Review.Methodist DeBakey cardiovascular journal · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Adam S HelmsDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Andrea D ThompsonDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Sharlene M DayDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary etiology of a diverse range of cardiomyopathies is now understood to be genetic, creating a new paradigm for targeting treatments on the basis of the underlying molecular cause. This review provides a genetic and etiologic context for the traditional clinical classifications of cardiomyopathy, including molecular subtypes that may exhibit differential responses to existing or emerging treatments. The authors describe several emerging cardiomyopathy treatments, including gene therapy, direct targeting of myofilament function, protein quality control, metabolism, and others. The authors discuss advantages and disadvantages of these approaches and indicate areas of high potential for short- and longer term efficacy.

Indexed as

AAV, adeno-associated virusACM, arrhythmogenic cardiomyopathyarrhythmogenic cardiomyopathyARVC, arrhythmogenic right ventricular cardiomyopathyATPase, adenosine triphosphataseDCM, dilated cardiomyopathydilated cardiomyopathyDMD, Duchenne muscular dystrophyDNA, DNADSP, desmoplakinFDA, U.S. Food and Drug AdministrationgeneticsGRT, gene replacement therapyGST, gene silencing therapyHCM, hypertrophic cardiomyopathyHR, homologous recombinationhypertrophic cardiomyopathyLNP, lipid nanoparticleLVOT, left ventricular outflow tractRNA, RNAtherapeuticsTTR, transthyretin

Identifiers

PMID35128211
PMCPMC8807730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.